Another anti-TIM-3 antibody (Sym023) is currently being tested in phase I clinical trials in patients with lymphoma refractory to currently available therapies, in monotherapy or in combination with anti-PD-1 (Sym021) or anti-LAG-3 (Sym022) antibodies (NCT03489343 and NCT03311412). The gene discussed is HAVCR2; the disease is lymphoma.